A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Annals of Oncology

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDI309PMID 16087696
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

  2005cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

  2004cited by this paper
• Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

  2004cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003cited by this paper
• Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2003cited by this paper
• The pemetrexed/gemcitabine combination in pancreatic cancer

  2002cited by this paper
• Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

  2002cited by this paper
• Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma

  2002cited by this paper
• Advanced pancreatic cancer--5 years on.

  2002cited by this paper
• A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

  2002cited by this paper
• Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.

  2001cited by this paper
• Estimating the world cancer burden: Globocan 2000

  2001cited by this paper
• Chemotherapy for resectable and advanced pancreatic cancer.

  2001cited by this paper
• Pancreatic and hepatobiliary cancers: New treatment possibilities for pancreatic and biliary tumours

  2000cited by this paper
• Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.

  2000cited by this paper
• Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.

  2000cited by this paper
• Missing quality of life data in cancer clinical trials: serious problems and challenges.

  1998cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil.

  1997cited by this paper
• A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.

  1996cited by this paper
• The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

  1993cited by this paper
• Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

  1992cited by this paper
• Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

  1975cited by this paper
• A new look at the statistical model identification

  1974cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• EffiXane—Non-interventional study on safety and effectiveness of nab-paclitaxel (Abraxane®) + gemcitabine as first-line treatment of metastatic PDAC in a daily routine setting

  2025cites this paper
• Nestin and SOX2 Maintain self-renewal Abilities of Different Pancreatic Cancer Stem Cell Populations

  2025cites this paper
• S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1

  2024cites this paper
• Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review

  2024cites this paper
• Chemotherapy and radiotherapy for advanced pancreatic cancer.

  2024cites this paper
• Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: A systematic review and network meta-analysis

  2024cites this paper
• A targetable pathway to eliminate TRA-1-60+/TRA-1-81+ chemoresistant cancer cells

  2023cites this paper
• Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation

  2022cites this paper
• Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan

  2022cites this paper
• Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial

  2021cites this paper
• Nonsurgical Management of Pancreatic Adenocarcinoma

  2021cites this paper
• A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer

  2021cites this paper
• Role of ARK5 in cancer and other diseases (Review)

  2021cites this paper
• Current controversies and advances in the management of pancreatic adenocarcinoma

  2021cites this paper
• Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients

  2021cites this paper
• Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain.

  2021cites this paper
• Clinical practice guidelines for the interventional treatment of advanced pancreatic cancer (5th edition)

  2021cites this paper
• Arterial infusion and arterial chemoembolization for pancreatic cancer

  2021cites this paper
• Strategies and methods for selecting suitable combined interventional therapy for pancreatic carcinoma

  2021cites this paper
• Study of efficacy and toxicity profile of gemcitabine and erlotinib based chemotherapy regimen in locally advanced (inoperable) and metastatic carcinoma pancreas

  2021cites this paper
• Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs

  2020cites this paper
• Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients

  2020cites this paper
• Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy: A retrospective analysis.

  2020cites this paper
• Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND).

  2019cites this paper
• Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study

  2019cites this paper
• Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer

  2019cites this paper
• Факторы, влияющие на эффективность комбинации гемцитабина и nab-паклитаксела (паклитаксел + альбумин) в российской популяции пациентов: результаты многоцентрового ретроспективного исследования

  2019cites this paper
• Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.

  2019cites this paper
• Special Section on Drug Delivery Technologies — Minireview Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer

  2019cites this paper
• FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer.

  2019cites this paper
• Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management

  2019cites this paper
• Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma

  2019cites this paper
• AMPK-related kinase 5 (ARK5) enhances gemcitabine resistance in pancreatic carcinoma by inducing epithelial-mesenchymal transition.

  2018cites this paper
• LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

  2018cites this paper
• Efficacy and Tolerability of Second‐line Nab‐paclitaxel and Gemcitabine After Failure of First‐line FOLFIRINOX for Advanced Pancreas Cancer: A Single‐institution Experience

  2018cites this paper
• Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta‐analysis

  2018cites this paper
• A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma

  2018cites this paper
• An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model

  2018cites this paper
• 6 Current Perspectives and Future Trends of Systemic Therapy in Advanced Pancreatic Carcinoma

  2018cites this paper
• Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer study of locally advanced or MPC patients. 7 The phase III trial, Metastatic

  2018cites this paper
• Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine

  2018cites this paper
• Conventional cytotoxic therapy 2 . 1 Monotherapy

  2018cites this paper
• Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer

  2018cites this paper
• Chemotherapy and radiotherapy for advanced pancreatic cancer.

  2018cites this paper
• Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

  2018cites this paper
• Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols

  2018cites this paper
• A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

  2018cites this paper
• Cytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed

  2018cites this paper
• Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta‐Analysis

  2018cites this paper
• Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta‐analysis

  2018influential citation
• Meta-analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment-associated toxicities

  2018cites this paper
• A pilot study investigating specific immune regulatory cells and microRNA in patients with advanced Pancreatic Adenocarcinoma treated with intravenous omega-3 fish oil infusion and Gemcitabine

  2018cites this paper
• Predictive Impact of Clinical Benefit in Chemotherapy-treated Advanced Pancreatic Cancer Patients in Northern Alberta

  2017cites this paper
• Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies.

  2017cites this paper
• Immunotherapy in pancreatic cancer treatment: a new frontier

  2017cites this paper
• Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials

  2017cites this paper
• Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?

  2017cites this paper
• All‐trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC‐1 by up‐regulating protein expression of deoxycytidine kinase

  2017cites this paper
• Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

  2017cites this paper
• Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems

  2017cites this paper
• Chemotherapy in the Management of Pancreatic Cancer

  2017cites this paper
• A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

  2017cites this paper
• Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts

  2017cites this paper
• Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer.

  2017cites this paper
• Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis

  2017cites this paper
• A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis

  2017cites this paper
• Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX

  2017cites this paper
• Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis

  2017cites this paper
• Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis

  2017cites this paper
• Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.

  2017cites this paper
• Management of Metastatic Pancreatic Adenocarcinoma.

  2016cites this paper
• Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis

  2016cites this paper
• Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer.

  2016cites this paper
• Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials

  2016cites this paper
• Curcumin AntiCancer Studies in Pancreatic Cancer

  2016cites this paper
• Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models

  2016cites this paper
• Pancreatic Cancer: Promises and Failures of Target Therapies.

  2016cites this paper
• Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review.

  2016cites this paper
• Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.

  2016cites this paper
• Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review.

  2016cites this paper
• NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

  2016cites this paper
• Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.

  2016cites this paper
• Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?

  2016cites this paper
• Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.

  2016cites this paper
• Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma

  2015cites this paper
• Erlotinib for advanced pancreatic cancer

  2015cites this paper
• Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies

  2015cites this paper
• Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer

  2015cites this paper
• Recent advances in pancreatic cancer: biology, treatment, and prevention.

  2015cites this paper
• Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.

  2015cites this paper
• Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

  2015cites this paper
• Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles1

  2015cites this paper
• Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials.

  2015cites this paper
• Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer

  2015cites this paper
• Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy

  2015cites this paper
• Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.

  2015cites this paper
• Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study

  2015cites this paper
• Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.

  2015cites this paper
• Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers

  2015cites this paper